What is the Australian Burden of Disease Study and why does it matter?

The Australian Burden of Disease Study is how the AIHW measures the impact of different health conditions on Australians — using disability-adjusted life years (DALYs), which combine years of life lost to premature death and years lived with disability. Conditions in the study are the ones government uses when deciding where to direct health funding, research grants, and policy attention. When ME/CFS was absent from the study, it was effectively invisible to that decision-making process. Its reinstatement means the condition will be counted and compared to others in the same framework.

What does the change in ME/CFS exercise recommendations mean for my care?

If you have ME/CFS and have been told to gradually increase your activity levels, it is worth discussing current guidance with your GP. In 2021, the UK's NICE guidelines changed their recommendation: they now explicitly advise against graded exercise therapy for ME/CFS because evidence showed it caused harm in people with post-exertional malaise — the worsening of symptoms after physical or mental activity that is characteristic of the condition. Australian guidance has not fully aligned with this yet, but the shift in international evidence is significant. The current clinical consensus is that pacing — managing activity to stay within your energy envelope — is preferable to pushing through symptoms.

ME/CFS back in Australia's Burden of Disease Study after 15 years

What just happened

After more than 15 years of absence, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has been reinstated as a standalone condition in Australia’s Burden of Disease Study. The Australian Institute of Health and Welfare (AIHW) will now measure ME/CFS using disability-adjusted life years (DALYs) — the same unit used to weigh the impact of cancer, heart disease, and mental health disorders in the national accounting that shapes government funding priorities.

The condition was removed from the study in 2011. For the years between, ME/CFS was not missing from Australian clinical practice — GPs saw it, patients lived with it, specialists were asked about it — but it was invisible to the system that decides where research money goes and which health priorities receive a budget line.

That changes now.

Both-and

What the reinclusion actually does

Being counted in the Burden of Disease Study is not the same as being adequately funded or clearly understood. But it is the administrative foundation for both. Emerge Australia, the peak organisation for people with ME/CFS in this country, described the reinclusion as a “significant acknowledgement of the substantial public health burden this condition imposes.” CEO Anne Wilson noted it would enable “informed policy development and resource allocation” — careful language that acknowledges the gap between measurement and action.

The full 2026 Australian Burden of Disease Study publishes in December. The DALY figures for ME/CFS, when they appear, will provide the first nationally standardised measurement of the condition’s impact in over a decade. How those figures compare to the burden of conditions that are currently better funded — and whether they shift the next federal budget conversation — is the question that follows from this step.

Emerge Australia is also conducting a national survey in partnership with Edith Cowan University to measure ME/CFS disease burden directly from affected people. That data will complement the AIHW’s population-level methodology with patient-sourced evidence.

What remains genuinely contested

ME/CFS sits in a complicated clinical and scientific space, and the Burden of Disease reinclusion doesn’t resolve that.

The name itself is contested. “Chronic fatigue syndrome” has long been criticised by patient advocates and some researchers as trivialising — fatigue is a symptom, not a diagnosis, and the label has historically made it easier to attribute the condition to psychological causes rather than physiological ones. “Myalgic encephalomyelitis” implies neuroinflammatory pathology; the evidence for this is accumulating but not settled.

The treatment evidence is more complex still. For years, graded exercise therapy (GET) and cognitive behavioural therapy (CBT) were standard-of-care recommendations, including in Australian general practice. In 2021, the NICE guidelines in the UK were substantially revised: NICE explicitly recommended against GET and significantly narrowed the role of CBT, after extensive review found the evidence base was weaker than previously understood and that GET in particular caused harm in patients with post-exertional malaise (PEM). PEM — the worsening of symptoms following physical or cognitive activity — is now understood as the hallmark feature of the condition and the clinical mechanism that makes push-through approaches harmful rather than helpful.

Australian clinical guidance has not uniformly caught up with that revision. The Burden of Disease reinclusion doesn’t fix this gap. What it does is signal that the condition is real, measurable, and significant — the precondition for the research investment needed to generate a better treatment evidence base.

Why this matters for people who have it

ME/CFS disproportionately affects women. Most studies find women are affected at approximately twice the rate of men. In the 35–55 year age group — where the condition often presents — many patients are navigating it alongside employment, caregiving, and broader physical changes.

The path to diagnosis is often long, adversarial, and demoralising. Patients describe years of being told their symptoms are anxiety, depression, deconditioning, or unexplained. Being told the health system can now formally measure and count the condition as a significant burden carries meaning that goes beyond the technical.

For anyone currently on a waiting list, in a diagnostic limbo, or in the position of having to justify their experience to a GP or employer: the AIHW now agrees the burden is real enough to quantify.

My two cents

For patients with ME/CFS: the December 2026 AIHW study is the one to watch. The DALY figures will tell us where ME/CFS sits relative to other conditions in the national burden accounting. Whether government acts on those figures depends on advocacy — Emerge Australia is the right organisation to follow for developments, and the national survey underway provides an opportunity to contribute directly to the evidence base.

For GPs: if you trained when GET was first-line, the 2021 NICE guidance represents a genuine shift in the evidence landscape and is worth reviewing. The central clinical principle — avoiding post-exertional malaise rather than pushing through it — is the clearest current international consensus. Explaining PEM to patients as a physiological feature, not a motivational one, often shifts the clinical relationship.

The system is starting to count. That is the beginning of something.

Verdict: yes — a meaningful shift in how ME/CFS sits within Australian health policy, worth understanding for anyone who sees or lives with this condition.

Sources cited

ME/CFS returns to the Australian Burden of Disease Study. Medical Republic, 13 August 2026. https://www.medicalrepublic.com.au/me-cfs-returns-to-the-australian-burden-of-disease-study/128150
Emerge Australia — ME/CFS peak body. https://www.emerge.org.au/
Australian Burden of Disease Study. Australian Institute of Health and Welfare. https://www.aihw.gov.au/reports-data/health-conditions-disability-deaths/burden-of-disease/overview
Myalgic encephalomyelitis/chronic fatigue syndrome: diagnosis and management. NICE guideline NG206, 2021. https://www.nice.org.uk/guidance/ng206